Spots Global Cancer Trial Database for topical
Every month we try and update this database with for topical cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations | NCT06239480 | Microcystic Lym... | QTORIN 3.9% Rap... Placebo | 6 Years - | Palvella Therapeutics, Inc. | |
| CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome | NCT04893486 | BCCs in Gorlin ... | PTX-022 Vehicle compara... | 18 Years - | Palvella Therapeutics, Inc. | |
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations | NCT06239480 | Microcystic Lym... | QTORIN 3.9% Rap... Placebo | 6 Years - | Palvella Therapeutics, Inc. | |
| Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma | NCT02213861 | Cutaneous T-Cel... | SHAPE | 18 Years - | TetraLogic Pharmaceuticals | |
| A Study to Examine the Safety and Toleration of PEP005 Topical Gel in Patients With Actinic Keratoses on the Top of the Hand | NCT00544297 | Actinic Keratos... | PEP005 gel | 18 Years - | Peplin | |
| Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses | NCT00107965 | Actinic Keratos... | PEP005 PEP005 PEP005 PEP005 PEP005 PEP005 PEP005 PEP005 | 18 Years - | Peplin | |
| Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005 | NCT00544258 | Actinic Keratos... | PEP005 | 18 Years - | Peplin | |
| Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses | NCT00375739 | Actinic Keratos... | PEP005 | 18 Years - | Peplin | |
| Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) | NCT03070691 | Basal Cell Carc... | LDE225B Vehicle | 18 Years - | Novartis | |
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations | NCT06239480 | Microcystic Lym... | QTORIN 3.9% Rap... Placebo | 6 Years - | Palvella Therapeutics, Inc. | |
| Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma | NCT00108121 | Basal Cell Carc... | PEP005 | 18 Years - | Peplin | |
| Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma | NCT02213861 | Cutaneous T-Cel... | SHAPE | 18 Years - | TetraLogic Pharmaceuticals | |
| Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use | NCT00535769 | Skin Cancer | Electronic + no... Electronic moni... | 18 Years - | Massachusetts General Hospital | |
| Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In Situ | NCT00329121 | Carcinoma, Squa... | PEP005 | 18 Years - | Peplin | |
| The Use of Picato® (Ingenol Mebutate) to Treat Actinic Keratosis in Standard Clinical Practice | NCT02594436 | Actinic Keratos... | Ingenol mebutat... | 18 Years - | LEO Pharma | |
| Evaluation of a Topical Treatment for Actinic Keratosis | NCT01921907 | Actinic Keratos... | AD17137 topical... Placebo | 30 Years - 90 Years | Assuta Hospital Systems | |
| Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients | NCT02239731 | Rash Due to Epi... | FDX104 (4% Doxy... | 18 Years - | Vyne Therapeutics Inc. | |
| Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel | NCT00239135 | Keratosis | PEP005 | 18 Years - | Peplin | |
| Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation | NCT01856543 | Invasive Breast... | Eucerin Mometasone Furo... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma | NCT00108134 | Basal Cell Carc... | PEP005 | 18 Years - | Peplin | |
| Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses | NCT00375739 | Actinic Keratos... | PEP005 | 18 Years - | Peplin | |
| The Use of Picato® (Ingenol Mebutate) to Treat Actinic Keratosis in Standard Clinical Practice | NCT02594436 | Actinic Keratos... | Ingenol mebutat... | 18 Years - | LEO Pharma | |
| Topical Vitamin D3, Diclofenac or a Combination of Both to Treat Basal Cell Carcinoma | NCT01358045 | Basal Cell Carc... | Diclofenac Diclofenac + Ca... Calcitriol | 18 Years - | Maastricht University Medical Center | |
| Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005 | NCT00544258 | Actinic Keratos... | PEP005 | 18 Years - | Peplin | |
| To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC | NCT00432185 | Superficial Bas... | PEP005 | 18 Years - | Peplin | |
| Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use | NCT00535769 | Skin Cancer | Electronic + no... Electronic moni... | 18 Years - | Massachusetts General Hospital | |
| Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In Situ | NCT00329121 | Carcinoma, Squa... | PEP005 | 18 Years - | Peplin | |
| Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use | NCT00535769 | Skin Cancer | Electronic + no... Electronic moni... | 18 Years - | Massachusetts General Hospital | |
| CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome | NCT04893486 | BCCs in Gorlin ... | PTX-022 Vehicle compara... | 18 Years - | Palvella Therapeutics, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
